Premium
The Neuropsychiatric Fluctuations Scale for Parkinson's Disease: A Pilot Study
Author(s) -
Schmitt Emmanuelle,
Krack Paul,
Castrioto Anna,
Klinger Helene,
Bichon Amelie,
Lhommée Eugénie,
Pelissier Pierre,
Fraix Valerie,
Thobois Stephane,
Moro Elena,
MartinezMartin Pablo
Publication year - 2018
Publication title -
movement disorders clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 18
ISSN - 2330-1619
DOI - 10.1002/mdc3.12607
Subject(s) - neuropsychology , novelty , parkinson's disease , psychology , motor symptoms , psychiatry , physical medicine and rehabilitation , cognition , disease , scale (ratio) , clinical psychology , medicine , social psychology , physics , quantum mechanics
Background Non‐motor fluctuations represent a main source of disability in Parkinson's disease (PD). Among them, neuropsychiatric fluctuations are the most frequent and are often under‐recognized by patients and physicians, partly because specific tools for assessment of neuropsychiatric fluctuations are lacking. Objective To develop a scale for detecting and evaluating the presence and the severity of neuropsychological symptoms during the ON and OFF phases of non‐motor fluctuations. Methods Neuropsychiatric symptoms reported by PD patients in the OFF‐ and the ON‐medication conditions were collected using different neuropsychiatric scales (BDI‐II, BAI, Young, VAS, etc.). Subsequently, tree phases of a pilot study was performed for cognitive pretesting, identification of ambiguous or redundant items (item reduction), and to obtain preliminary data of acceptability of the new scale. In all the three phases, the scale was applied in both the OFF and ON condition during a levodopa challenge. Results Twenty items were selected for the final version of the neuropsychiatric fluctuation scale (NFS): ten items measured the ON neuropsychological symptoms and ten items the OFF neuropsychological manifestations. Each item rated from 0‐3, providing respective subscores from 0 to 30. Conclusions Once validated, our NFS can be used to identify and quantify neuropsychiatric fluctuations during motor fluctuations. The main novelty is that it could be used in acute settings. As such, the NFS can assess the neuropsychiatric state of the patient at the time of examination. The next step will be to validate the NFS to be used in current practice.